Figure 5

Fluoxetine treatment reverses the depressive-like phenotypes induced by 24-hour-restraint.

(A) Experiment design in order to test the effect of fluoxetine (flx) treatment. (B) The sucrose consumption in the sucrose preference test. (2-way ANOVA, stress × durg: p < 0.01, drug: p = 0.03; stress: p < 0.01, N = C:23, R:28, flx-C:28, flx-R:28). (C) The struggling time before the first abandon in the forced swim test (2-way ANOVA, stress×durg: p = 0.2271; drug: p = 0.092; stress: p < 0.01; N = C:30, R:30, flx-C:29, flx-R:30). (D) The total time of immobility in the forced swim test (2-way ANOVA, stress×durg: p < 0.01; drug: p = 0.095; stress: p < 0.05, N = C:30, R:30, flx-C:29, flx-R:30). (E) The percentage of freezing in the fear condition test (2-way ANOVA, stress × durg: p = 0.25; drug: p < 0.001; stress: p < 0.01, N = C:30, R:30, flx-C:29, flx-R:27). (F) The number of Brdu⁺ cells (2-way ANOVA, stress × durg: p = 0.62; drug: p < 0.01; stress: p = 0.09, N = C:4, R:4, flx-C:3, flx-R:3). (G,H) Changes of ATP concentration level in the PFC (G) (2-way ANOVA, stress × durg: p = 0.945; drug: p < 0.05; stress: p = 0.436, N = 5 for each group) and hippocampus (H) (2-way ANOVA, stress × durg: p < 0.01; drug: p = 0.25; stress: p = 0.73, N = 5 for each group). The asterisks in the figures showed the significant interactions of subgroups detected by post-hoc tests (Tukey Honest Significant Differences): *P < 0.05, **P < 0.01, ***P < 0.001. Data are presented as mean ± SEM.